Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., discusses if she thinks biosimilars will play a role in lowering costs in coming years.
Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., discusses if she thinks biosimilars will play a role in lowering costs in coming years.
Transcript
With the first 2 anticancer biosimilars now on the market and others waiting to enter, do you foresee biosimilars playing a role in lowering costs in the coming years?
I’d like to say yes because you think that competition is a good thing, but in all reality, that’s not been something that we can control. When Neulasta had the biosimilar come out, a lot of payers were like you need to change right away and you need to use Fulphila and you need to use Udenica, and then 6 months later they were like, “Oh no, we want you to go back to using Neulasta,” because now they got a rebate from Neulasta and the Amgen products.
So, we didn’t have control over that, and the same thing with Mvasi—we have some patients that we’re not going to switch patients that are in the middle of therapy. We have some insurances that are saying if you have a prior authorization, you can continue to use it, but if you’re prior authorization expires, you have to change them to the biosimilars. But, Mvasi has not been approved for indications for ovarian cancer. So, even though we might use it for another therapy, we can’t use it in that diagnosis. So, I don’t know.
Also, one of the things that is really interesting is they’re coming out with their own Q-code, their own J code. They’re being marketed like the brand, and they’re not really cheap because they don’t want to disrupt [average sales price] because they had that happen when we had other biosimilars came out. So, I guess it remains to be seen if they’re being treated like a brand drug. Are they going to be just as expensive down the line? I guess we’ll see.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More